NCNA - NuCana plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.09
+0.20 (+2.98%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.89
Open7.00
Bid0.00 x 1000
Ask0.00 x 1100
Day's Range6.85 - 7.10
52 Week Range4.01 - 20.08
Volume28,154
Avg. Volume87,376
Market Cap247.245M
Beta (3Y Monthly)3.13
PE Ratio (TTM)N/A
EPS (TTM)-0.63
Earnings DateNov 22, 2019 - Dec 2, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1,773.18
Trade prices are not sourced from all markets
  • Lilly's Pancreatic Cancer Candidate Fails in Phase III Study
    Zacks

    Lilly's Pancreatic Cancer Candidate Fails in Phase III Study

    Lilly's (LLY) immunotherapy candidate, pegilodecakin, falls short of meeting the primary endpoint of OS benefit in a phase III study investigating its usage in metastatic pancreatic cancer.

  • Novavax Begins Phase III Study on Influenza Vaccine Candidate
    Zacks

    Novavax Begins Phase III Study on Influenza Vaccine Candidate

    Novavax (NVAX) starts a pivotal late-stage study on its pipeline candidate NanoFlu influenza vaccine in senior patients. Shares up.

  • What Percentage Of NuCana plc (NASDAQ:NCNA) Shares Do Insiders Own?
    Simply Wall St.

    What Percentage Of NuCana plc (NASDAQ:NCNA) Shares Do Insiders Own?

    A look at the shareholders of NuCana plc (NASDAQ:NCNA) can tell us which group is most powerful. Generally speaking...

  • Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review
    Zacks

    Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review

    The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.

  • Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study
    Zacks

    Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study

    Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.

  • FDA Grants Orphan Drug Status to Acceleron's PAH Candidate
    Zacks

    FDA Grants Orphan Drug Status to Acceleron's PAH Candidate

    The FDA assigns an orphan drug status to Acceleron's (XLRN) investigational therapy sotatercept for the treatment of patients with pulmonary arterial hypertension. Shares inch up.

  • NuCana plc (NCNA) Shares March Higher, Can It Continue?
    Zacks

    NuCana plc (NCNA) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in NuCana plc (NCNA).

  • Acorda (ACOR) Down More Than 60% in 3 Months: Here's Why
    Zacks

    Acorda (ACOR) Down More Than 60% in 3 Months: Here's Why

    Acorda's (ACOR) lead MS drug Ampyra is hit by generic rivalry in the United States, which is hurting the company's top line. Parkinson's disease drug Inbrija can be an ideal replacement.

  • Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease
    Zacks

    Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease

    The FDA assigns an orphan drug status to Akari's (AKTX) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, which is a rare disease.

  • GlobeNewswire

    NuCana to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    NuCana plc (NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Morgan Stanley 17th Annual Global Healthcare Conference in New York, NY. NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.  While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated.

  • GlobeNewswire

    NuCana to Participate in Citi’s 14th Annual Biotech Conference

    NuCana plc (NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at Citi’s 14th Annual Biotech Conference in Boston on September 5th, 2019. NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.  While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated.

  • GlobeNewswire

    NuCana Reports Second Quarter 2019 Financial Results and Provides Business Update

    Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom, Aug. 21,.

  • NuCana Stops Patient Enrollment in Pancreatic Cancer Study
    Zacks

    NuCana Stops Patient Enrollment in Pancreatic Cancer Study

    NuCana (NCNA) suspends patient enrollment in the phase III study on Acelarin, currently evaluated for treating patients with metastatic pancreatic cancer, who were unfit for combination chemotherapy.

  • MarketWatch

    NuCana stock falls 21% after company suspends patient enrollment in pancreatic cancer trial

    Shares of NuCana Plc fell 21% on Tuesday after the company announced it had suspended the enrollment of new patients in a late-stage trial of a pancreatic cancer drug. Researchers were studying the safety and efficacy of NuCana's drug Acelarin in patients with metastatic pancreatic cancer, comparing it with the chemotherapy treatment gemcitabine. An independent committee reviewed interim data from the Phase 3 study, found that the study was unlikely to reach its primary goal and recommended suspending recruitment, though patients who are deriving benefit from Acelarin will be allowed to continue treatment, NuCana said. Shares of NuCana have fallen 60.3% so far this year. The S&P 500 has gained 16.2%. (edited)

  • GlobeNewswire

    Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study ACELARATE Has Been Suspended Following a Prespecified Futility Analysis

    NuCana plc (NCNA) reported that it has been informed by the Clatterbridge Cancer Centre, the sponsor of the ongoing  Phase III ACELARATE study, that the enrollment of new patients has been suspended on the advice of the Independent Safety and Data Monitoring Committee (ISDMC) following completion of a prespecified futility analysis.  This study has enrolled 200 patients with metastatic pancreatic cancer who were not considered suitable for combination chemotherapy and is designed to evaluate the efficacy and safety of Acelarin monotherapy compared to gemcitabine, with further exploration of patient sub-groups that may derive additional benefit from Acelarin. A futility analysis was included in the ACELARATE study design to assess the likelihood of the study achieving its primary objective of Acelarin monotherapy demonstrating at least a 42% reduction in risk of death compared to gemcitabine.  This analysis indicated that this efficacy objective was unlikely to be met in this difficult to treat patient population.  Upon review of the interim data by the ISDMC, the sponsor decided to suspend recruitment, allow the data to mature and conduct additional sub-group analyses.

  • Analysts Recommend These 2 Falling Knives
    GuruFocus.com

    Analysts Recommend These 2 Falling Knives

    NuCana, GlycoMimetics present interesting opportunities Continue reading...

  • NuCana Initiates Dosing in Phase I Study for Solid Tumors
    Zacks

    NuCana Initiates Dosing in Phase I Study for Solid Tumors

    NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.

  • GlobeNewswire

    NuCana Announces First Patients Dosed in Phase I Study of NUC-7738

    NuCana plc (NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, today announced that the first patients have been dosed in the Phase I study of NUC-7738. This is the third ProTide NuCana has advanced to clinical studies and further broadens the therapeutic scope of the ProTide portfolio. NUC-7738 is NuCana’s ProTide transformation of 3’-deoxyadenosine (or cordycepin), a novel nucleoside analog with a unique mode of action, that has shown potent anti-cancer activity in preclinical studies.

  • NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag
    Zacks

    NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag

    The FDA confers an orphan drug designation on NuCana's (NCNA) pipeline candidate, Acelarin, for treating patients with biliary tract cancer

  • Benzinga

    The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 12) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp ...

  • GlobeNewswire

    NuCana Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Acelarin® for the Treatment of Biliary Tract Cancer

    NuCana plc (NCNA) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company’s investigational drug, Acelarin® (NUC-1031), for the treatment of biliary tract cancer. Acelarin is a new chemical entity and is NuCana’s ProTide transformation of gemcitabine.

  • GlobeNewswire

    NuCana to Present at the Jefferies 2019 Healthcare Conference

    NuCana plc (NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies 2019 Healthcare Conference in New York, NY. The presentation will be webcast live and available for replay under “Events & Presentations” in the Investors section of the Company's website at www.nucana.com. NuCana® is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.

  • GlobeNewswire

    NuCana Reports First Quarter 2019 Financial Results and Provides Business Update

    Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom, May 14,.

  • GlobeNewswire

    NuCana to Participate in the William Blair 3rd Late-Stage Therapeutics Conference

    NuCana plc (NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that Don Munoz, Chief Financial Officer, will host one-on-one meetings at the William Blair 3rd Late-Stage Therapeutics Conference in New York, NY. NuCana® is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.  While these conventional agents remain part of the standard of care for the treatment of many solid tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated.

  • Introducing NuCana (NASDAQ:NCNA), The Stock That Dropped 10% In The Last Year
    Simply Wall St.

    Introducing NuCana (NASDAQ:NCNA), The Stock That Dropped 10% In The Last Year

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Over the last month the NuCana plc (NASDAQ:NCNA) has been much stronger than before, rebounding by 43%. But that does...